• Moleculin Biotech won a Mexican patent covering its lung-targeted liposomal formulation of Annamycin.
• The protection runs through Nov. 23, 2040, extending exclusivity for the technology in Mexico.
• Annamycin is being evaluated in the pivotal MIRACLE trial for relapsed or refractory acute myeloid leukemia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230825PRIMZONEFULLFEED9832071) on September 23, 2026, and is solely responsible for the information contained therein.